19 Citations (Scopus)

Abstract

Combined catechol-O-methyl-transferase-inhibition and Levodopa-Carbidopa intestinal gel (LCIG) infusion has the potential to reduce LCIG daily dose and the costs of this therapy. In this retrospective analysis, we report on Parkinson's disease (PD) patients on LCIG with concomitant Opicapone. In 11 patients, the introduction of Opicapone led to LCIG daily dose being reduced by 24.8% (p = 0.05) without any significant worsening of dyskinesia. Three patients withdrew from Opicapone due to side effects or inefficacy. LCIG daily dose reduction could lead to cost savings of £142,820.63/year in the United Kingdom while maintaining clinical care.

Original languageEnglish
Pages (from-to)1535-1539
Number of pages5
JournalJournal of Parkinson's Disease
Volume10
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • Catechol-O-methyl-transferase-inhibitor
  • cost savings
  • intrajejunal Levodopa infusion
  • Levodopa-Carbidopa intestinal gel
  • Opicapone

Fingerprint

Dive into the research topics of 'Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?'. Together they form a unique fingerprint.

Cite this